secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001567264-24-000013
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics enters collaboration with SAKK for Phase 2 breast cancer study of INT230-6
--------------------------------------------------------------------------------

- SAKK to conduct Phase 2 of INVINCIBLE-4 Study testing INT230-6 plus standard of care vs standard of care alone in neoadjuvant triple negative breast cancer in Europe.
- Intensity will supply INT230-6 and provide up to approximately $3.0 million in funding for the study.
- Indemnification: SAKK indemnifies Intensity for claims from its study duties; Intensity indemnifies SAKK for issues from drug manufacturing, packaging, labeling.
- Term runs until final clinical study report; either party may terminate for material breach, negligible scientific value, safety, or significant recruitment delay (>12 months).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/0001567264-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/intensity-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001567264-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer